High importance EXO Biologics & ExoXpert achieve two critical industry-first milestones for the exosome field
High importance EXO Biologics completes dosing of first cohort in first EMA-approved MSC-based exosome clinical trial
EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply.
High importance ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes
Research Paper : EVs From MS Umbilical Cord Cells Exert Protection Against Oxidative Stress and Fibrosis in a Rat Model of BPD
EXO Biologics Granted Orphan Drug Designation by FDA for EXOB-001 for Prevention of BPD in Preterm newborns.
EXO Biologics Received FDA Rare Pediatric Disease Designation for EXOB-001 for Prevention of BPD in Preterm newborns.